UBS Group
IOVA icon

UBS Group’s Iovance Biotherapeutics IOVA Stock Holding History

UBS Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-15,000
Closed -$415K – 8166
2019
Q4 		$415K Buy
+15,000
New +$341K ﹤0.01% 5004

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

UBS Group's IOVA Position: Q2 2026 in Review

UBS Group reduced its Iovance Biotherapeutics (IOVA) stake by 33% in Q2 2026, selling an estimated $2.37M and leaving 1,291,664 shares worth $5.37M. The position accounts for ﹤0.01% of the portfolio, ranked #4102.

UBS Group first reported a position in IOVA in Q1 2015 and has held it in 46 quarters since. The position peaked at $20M in Q4 2024. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • UBS Group held 1,291,664 shares of Iovance Biotherapeutics worth $5.37M as of Q2 2026.
  • UBS Group sold 625,040 Iovance Biotherapeutics shares in Q2 2026, an estimated $2.37M.
  • Iovance Biotherapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4102 holding.
  • UBS Group first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 46 quarters since.
  • UBS Group's Iovance Biotherapeutics position peaked at $20M in Q4 2024.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.